Europe
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
Novartis acquired Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with Vedere Bio’s gene therapy platforms for ophthalmic disorders.
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease causing muscular pain and cognitive challenges.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The report showed that in some cases, people who have recovered from the virus continued to exhibit significant cognitive deficits.
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Bayer is paying $2 billion upfront for AskBio’s AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.
Days after the U.S. FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G). The analysis was presented at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting.
PRESS RELEASES